Atopic Dermatitis

A study out of Japan found the burden on patients with atopic dermatitis and their caregivers can increase with age and disease severity.

The phase 3b/4 LEVEL-UP study assessed adolescents and adults with moderate to severe atopic dermatitis.

Roflumilast cream 0.15% is being evaluated for patients with mild to moderate atopic dermatitis down to 6 years.

Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.

David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

Robert Sidbury, MD, MPH, addresses the similarities and differences between the AAD’s recent atopic dermatitis guidelines and other guidelines from various groups and countries.

Kristine Kucera, PA-C, MPAS, DHS, discusses prescribing a PDE-4 inhibitor for Mickey Bryson's psoriasis and atopic dermatitis, emphasizing the absence of FDA-approved medications like JAK inhibitors, while Bryson underscores the challenges of daily injections, likening it to insulin use.

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Jonathan Silverberg, MD, PhD, MPH, presented his tips for effectively treating atopic dermatitis without worsening autoimmune comorbidities.

Improvements in patient-reported outcomes were higher among patients treated with upadacitinib 30mg versus 15mg.

In this recently presented poster, a dermatology expert draws on clinical experience to reveal why healthcare providers switch treatments for atopic dermatitis (AD). The expert also examines how these reasons vary with disease stage and patient demographics, offering nuanced insights into AD management.

Turn Therapeutics' Bradley Burnam recently spoke with Dermatology Times.

Kristine Kucera, PA-C, MPAS, DHS, and Mickey Bryson discuss Mickey's atopic dermatitis diagnostic process and the ineffective initial treatments, which included topical therapies, homeopathic remedies, and prednisone steroids.

James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.

The trial results indicated 3 significant improvements across all AHFD subtypes with dupilumab treatment compared to placebo.

Significant improvements were observed in EASI scores across all anatomical regions, regardless of patient age or specific body region.

Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative.

Learn more about the in-depth topics covered in the May 2024 supplement of Dermatology Times.

Supportive data for roflumilast in adults and children 6 years of age and older stems from the INTEGUMENT studies.

Misinformation regarding the use of corticosteroids remains persistent and may have implications on patient care.

A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.

Results of a recent study show RECAP's impact on adult Asian patients with AD.

Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.

Researchers found that abrocitinib demonstrated rapid, sustained, and deep improvements in several important domains of itch-dominant AD.